Eleftha 150mg Injection

About

Eleftha 150mg Injection contains Trastuzumab as the active ingredient and is indicated for the treatment of HER2‑positive breast cancer. In HER2‑positive patients, breast cancer cells produce excessive amounts of HER2 protein, which promotes rapid tumor growth by sending strong growth signals to cancer cells. This medication is also used to treat metastatic gastric cancer with elevated HER2 protein levels.

HER2‑positive breast cancers are generally more aggressive in nature. Eleftha works as targeted therapy, selectively blocking the proteins responsible for cancer cell growth, development, and spread. Effective contraception should be used during treatment and for at least seven months after the final dose.

Eleftha 150mg Injection is not recommended for patients under 18 years of age, those with severe breathing problems, or patients requiring oxygen therapy. Inform your physician if you have any heart conditions, experience breathlessness, or have previously undergone cancer treatment. Also, disclose all medications you are currently taking, including prescription drugs, over‑the‑counter medicines, supplements, and herbal products, before starting treatment.

Serious

• Heart problems
• Breathing difficulties
• Kidney problems
• Allergic reactions

Common

• Fever
• Dizziness
• Visual disturbances
• Nosebleeds or runny nose
• Loss of appetite
• Weight loss
• Hair loss
• Nail disorders
• Bruising
• Dry mouth
• Muscle pain
• Asthma/lung disorders
• Liver inflammation

Safety Measures

Alcohol - Consult your doctor to determine whether it is safe to consume alcohol during treatment with Eleftha 150mg Injection.
Pregnancy - Discuss with your physician before taking Eleftha 150mg Injection if you are pregnant or suspect you may be pregnant. Do not use this medicine during pregnancy unless specifically advised by your doctor, as it may cause harm to the unborn baby.
BreastFeeding - Avoid breastfeeding during treatment with Eleftha 150mg Injection and for at least seven months after the final dose.
Liver - Inform your physician if you have any liver disorders before starting Eleftha 150mg Injection, as dosage adjustments may be required in cases of severe liver impairment.
Kidney - Eleftha 150mg Injection is likely safe for patients with kidney disease. Available data suggests that dose adjustment may not be necessary; however, please consult your doctor for individual advice.


Disclaimer

Med E Hub is committed to delivering reliable, expert-reviewed information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis, or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.